[SCHEDULE 13G/A] MacroGenics, Inc. SEC Filing
The Frazier Life Sciences reporting group disclosed specific holdings in MacroGenics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 1,549,193 shares representing 2.5% of the 63,090,323 shares outstanding used for the percentage calculation. Other reporting entities hold 925,809 shares (1.5%), 575,150 shares (0.9%) and 125,513 shares (0.2%).
The filing states that voting and dispositive power for these shares is shared rather than sole and corrects prior attributions by clarifying that members of certain investment committees are not attributed beneficial ownership of the securities held by the respective funds. The statement also notes the reporters do not admit broader beneficial ownership or group status beyond what is disclosed.
Il gruppo di segnalazione Frazier Life Sciences ha comunicato partecipazioni specifiche in azioni ordinarie di MacroGenics. Frazier Life Sciences Public Fund, L.P. detiene direttamente 1.549.193 azioni, pari al 2,5% delle 63.090.323 azioni in circolazione utilizzate per il calcolo della percentuale. Altri enti segnalanti detengono rispettivamente 925.809 azioni (1,5%), 575.150 azioni (0,9%) e 125.513 azioni (0,2%).
La comunicazione precisa che il potere di voto e di disposizione su queste azioni 猫 condiviso e non esclusivo, e rettifica precedenti attribuzioni chiarendo che i membri di alcuni comitati d'investimento non sono attribuiti come titolari della propriet脿 beneficiaria dei titoli detenuti dai relativi fondi. La nota specifica inoltre che i dichiaranti non riconoscono una pi霉 ampia titolarit脿 beneficiaria o lo status di gruppo oltre quanto reso noto.
El grupo informante Frazier Life Sciences divulg贸 participaciones espec铆ficas en acciones ordinarias de MacroGenics. Frazier Life Sciences Public Fund, L.P. posee directamente 1.549.193 acciones, que representan el 2,5% de las 63.090.323 acciones en circulaci贸n usadas para el c谩lculo del porcentaje. Otros entes informantes poseen respectivamente 925.809 acciones (1,5%), 575.150 acciones (0,9%) y 125.513 acciones (0,2%).
La presentaci贸n indica que el poder de voto y el poder de disposici贸n sobre estas acciones es compartido en lugar de exclusivo y corrige atribuciones anteriores aclarando que los miembros de ciertos comit茅s de inversi贸n no son atribuidos como titulares beneficiarios de los valores mantenidos por los respectivos fondos. La declaraci贸n tambi茅n se帽ala que los informantes no reconocen una titularidad beneficiaria m谩s amplia ni condici贸n de grupo m谩s all谩 de lo divulgado.
Frazier Life Sciences 氤搓碃 攴鸽９鞚� MacroGenics 氤错喌欤检棎 雽�頃� 甑泊鞝� 氤挫湢毳� 瓿奠嫓頄堨姷雼堧嫟. Frazier Life Sciences Public Fund, L.P.電� 歆侅爲鞝侅溂搿� 1,549,193欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 牍勳湪 瓿勳偘鞐� 靷毄霅� 齑� 63,090,323欤�鞚� 2.5%鞐� 頃措嫻頃╇媹雼�. 旮绊儉 氤搓碃 欤检泊霌れ潃 臧侁皝 925,809欤� (1.5%), 575,150欤� (0.9%), 125,513欤� (0.2%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
氤搓碃靹滌棎電� 鞚措摛 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇澊 雼弲鞚� 鞎勲媽 瓿惦彊鞙茧 頄夓偓霅滊嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 鞚茧秬 韴瀽鞙勳洂須� 甑劚鞗愲摛鞚� 頃措嫻 韼�霌滉皜 氤挫湢頃� 歃濌秾鞚� 鞁れ鞝� 靻岇湢鞛愲 攴�靻嶋悩歆� 鞎婋姅雼る姅 鞝愳潉 氇呿檿頌� 頃橃棳 鞚挫爠鞚� 攴�靻� 旮半鞚� 鞝曥爼頃滊嫟瓿� 氚濏瀳瓿� 鞛堨姷雼堧嫟. 霕愴暅 鞁犼碃鞛愲摛鞚� 瓿店皽霅� 雮挫毄 氩旍渼毳� 雱橃柎靹� 雿� 雱撿潃 鞁れ鞝� 靻岇湢甓岇澊雮� 攴鸽９ 歆�鞙勲ゼ 鞚胳爼頃橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟.
Le groupe d茅clarant Frazier Life Sciences a divulgu茅 des participations sp茅cifiques dans les actions ordinaires de MacroGenics. Frazier Life Sciences Public Fund, L.P. d茅tient directement 1 549 193 actions, repr茅sentant 2,5% des 63 090 323 actions en circulation utilis茅es pour le calcul du pourcentage. D'autres entit茅s d茅clarantes d茅tiennent respectivement 925 809 actions (1,5%), 575 150 actions (0,9%) et 125 513 actions (0,2%).
Le d茅p么t indique que le pouvoir de vote et le pouvoir de disposition sur ces actions sont 辫补谤迟补驳茅蝉 plut么t qu'exclusifs et corrige des attributions ant茅rieures en pr茅cisant que les membres de certains comit茅s d'investissement ne se voient pas attribuer la qualit茅 de propri茅taires effectifs des titres d茅tenus par les fonds concern茅s. La d茅claration pr茅cise 茅galement que les d茅clarants n'admettent pas une propri茅t茅 b茅n茅ficiaire plus large ni un statut de groupe au-del脿 de ce qui est divulgu茅.
Die Meldengruppe Frazier Life Sciences hat konkrete Best盲nde an Stammaktien von MacroGenics offengelegt. Frazier Life Sciences Public Fund, L.P. h盲lt direkt 1.549.193 Aktien, was 2,5% der f眉r die Prozentberechnung zugrunde gelegten 63.090.323 ausstehenden Aktien entspricht. Weitere meldende Einheiten halten jeweils 925.809 Aktien (1,5%), 575.150 Aktien (0,9%) und 125.513 Aktien (0,2%).
Die Einreichung gibt an, dass Stimm- und Verf眉gungsmacht an diesen Aktien geteilt und nicht ausschlie脽lich ausge眉bt wird und korrigiert fr眉here Zuschreibungen, indem sie klarstellt, dass Mitglieder bestimmter Investmentaussch眉sse nicht als wirtschaftliche Eigent眉mer der von den jeweiligen Fonds gehaltenen Wertpapiere zugerechnet werden. Die Erkl盲rung weist au脽erdem darauf hin, dass die Meldenden keine weitergehende wirtschaftliche Eigent眉merschaft oder Gruppenzugeh枚rigkeit 眉ber das Offenlegte hinaus anerkennen.
- Correction of prior attribution errors improves accuracy of beneficial ownership records.
- Exact share counts and percentages disclosed (e.g., 1,549,193 shares = 2.5%) provide clear transparency.
- No reporting person holds a controlling stake (>5%), indicating limited influence over MacroGenics.
- All reported positions reflect shared voting and dispositive power, so no sole control is reported.
Insights
TL;DR: Frazier funds hold modest, non-controlling stakes in MacroGenics; the amendment clarifies prior attribution errors and discloses exact positions.
The filing provides precise share counts and percentages for multiple Frazier-controlled funds, with the largest single reported holding at 1,549,193 shares (2.5%) based on 63,090,323 shares outstanding. From an investor-analysis perspective, these stakes are below a controlling threshold and are disclosed as shared voting and dispositive power. The amendment improves record accuracy by removing prior attributions to individual committee members, reducing ambiguity about who exercises authority over the positions.
TL;DR: The amendment tightens governance disclosures by clarifying that investment committees are not individually attributed beneficial ownership.
The filing corrects earlier filings by stating that investment committees managing certain general partners act by majority vote and that committee members should not be attributed beneficial ownership of the funds' securities. It also confirms no sole voting or dispositive power is claimed for the reporting persons, and includes a joint filing agreement as an exhibit. These clarifications enhance transparency in ownership reporting without asserting control or group affiliation beyond the reported holdings.
Il gruppo di segnalazione Frazier Life Sciences ha comunicato partecipazioni specifiche in azioni ordinarie di MacroGenics. Frazier Life Sciences Public Fund, L.P. detiene direttamente 1.549.193 azioni, pari al 2,5% delle 63.090.323 azioni in circolazione utilizzate per il calcolo della percentuale. Altri enti segnalanti detengono rispettivamente 925.809 azioni (1,5%), 575.150 azioni (0,9%) e 125.513 azioni (0,2%).
La comunicazione precisa che il potere di voto e di disposizione su queste azioni 猫 condiviso e non esclusivo, e rettifica precedenti attribuzioni chiarendo che i membri di alcuni comitati d'investimento non sono attribuiti come titolari della propriet脿 beneficiaria dei titoli detenuti dai relativi fondi. La nota specifica inoltre che i dichiaranti non riconoscono una pi霉 ampia titolarit脿 beneficiaria o lo status di gruppo oltre quanto reso noto.
El grupo informante Frazier Life Sciences divulg贸 participaciones espec铆ficas en acciones ordinarias de MacroGenics. Frazier Life Sciences Public Fund, L.P. posee directamente 1.549.193 acciones, que representan el 2,5% de las 63.090.323 acciones en circulaci贸n usadas para el c谩lculo del porcentaje. Otros entes informantes poseen respectivamente 925.809 acciones (1,5%), 575.150 acciones (0,9%) y 125.513 acciones (0,2%).
La presentaci贸n indica que el poder de voto y el poder de disposici贸n sobre estas acciones es compartido en lugar de exclusivo y corrige atribuciones anteriores aclarando que los miembros de ciertos comit茅s de inversi贸n no son atribuidos como titulares beneficiarios de los valores mantenidos por los respectivos fondos. La declaraci贸n tambi茅n se帽ala que los informantes no reconocen una titularidad beneficiaria m谩s amplia ni condici贸n de grupo m谩s all谩 de lo divulgado.
Frazier Life Sciences 氤搓碃 攴鸽９鞚� MacroGenics 氤错喌欤检棎 雽�頃� 甑泊鞝� 氤挫湢毳� 瓿奠嫓頄堨姷雼堧嫟. Frazier Life Sciences Public Fund, L.P.電� 歆侅爲鞝侅溂搿� 1,549,193欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 牍勳湪 瓿勳偘鞐� 靷毄霅� 齑� 63,090,323欤�鞚� 2.5%鞐� 頃措嫻頃╇媹雼�. 旮绊儉 氤搓碃 欤检泊霌れ潃 臧侁皝 925,809欤� (1.5%), 575,150欤� (0.9%), 125,513欤� (0.2%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
氤搓碃靹滌棎電� 鞚措摛 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇澊 雼弲鞚� 鞎勲媽 瓿惦彊鞙茧 頄夓偓霅滊嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, 鞚茧秬 韴瀽鞙勳洂須� 甑劚鞗愲摛鞚� 頃措嫻 韼�霌滉皜 氤挫湢頃� 歃濌秾鞚� 鞁れ鞝� 靻岇湢鞛愲 攴�靻嶋悩歆� 鞎婋姅雼る姅 鞝愳潉 氇呿檿頌� 頃橃棳 鞚挫爠鞚� 攴�靻� 旮半鞚� 鞝曥爼頃滊嫟瓿� 氚濏瀳瓿� 鞛堨姷雼堧嫟. 霕愴暅 鞁犼碃鞛愲摛鞚� 瓿店皽霅� 雮挫毄 氩旍渼毳� 雱橃柎靹� 雿� 雱撿潃 鞁れ鞝� 靻岇湢甓岇澊雮� 攴鸽９ 歆�鞙勲ゼ 鞚胳爼頃橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟.
Le groupe d茅clarant Frazier Life Sciences a divulgu茅 des participations sp茅cifiques dans les actions ordinaires de MacroGenics. Frazier Life Sciences Public Fund, L.P. d茅tient directement 1 549 193 actions, repr茅sentant 2,5% des 63 090 323 actions en circulation utilis茅es pour le calcul du pourcentage. D'autres entit茅s d茅clarantes d茅tiennent respectivement 925 809 actions (1,5%), 575 150 actions (0,9%) et 125 513 actions (0,2%).
Le d茅p么t indique que le pouvoir de vote et le pouvoir de disposition sur ces actions sont 辫补谤迟补驳茅蝉 plut么t qu'exclusifs et corrige des attributions ant茅rieures en pr茅cisant que les membres de certains comit茅s d'investissement ne se voient pas attribuer la qualit茅 de propri茅taires effectifs des titres d茅tenus par les fonds concern茅s. La d茅claration pr茅cise 茅galement que les d茅clarants n'admettent pas une propri茅t茅 b茅n茅ficiaire plus large ni un statut de groupe au-del脿 de ce qui est divulgu茅.
Die Meldengruppe Frazier Life Sciences hat konkrete Best盲nde an Stammaktien von MacroGenics offengelegt. Frazier Life Sciences Public Fund, L.P. h盲lt direkt 1.549.193 Aktien, was 2,5% der f眉r die Prozentberechnung zugrunde gelegten 63.090.323 ausstehenden Aktien entspricht. Weitere meldende Einheiten halten jeweils 925.809 Aktien (1,5%), 575.150 Aktien (0,9%) und 125.513 Aktien (0,2%).
Die Einreichung gibt an, dass Stimm- und Verf眉gungsmacht an diesen Aktien geteilt und nicht ausschlie脽lich ausge眉bt wird und korrigiert fr眉here Zuschreibungen, indem sie klarstellt, dass Mitglieder bestimmter Investmentaussch眉sse nicht als wirtschaftliche Eigent眉mer der von den jeweiligen Fonds gehaltenen Wertpapiere zugerechnet werden. Die Erkl盲rung weist au脽erdem darauf hin, dass die Meldenden keine weitergehende wirtschaftliche Eigent眉merschaft oder Gruppenzugeh枚rigkeit 眉ber das Offenlegte hinaus anerkennen.
FAQ
How many MacroGenics (MGNX) shares does Frazier Life Sciences Public Fund hold?
What percentage of MGNX does Frazier Life Sciences XI, L.P. own?
Do any Frazier reporting persons claim sole voting or dispositive power over MGNX shares?
What outstanding share base was used to calculate percentages in the filing?
Does the filing change prior ownership attributions?
